Key Highlights
- Seaport Therapeutics appoints Dr. David Wheadon to its Board of Directors.
- Dr. Wheadon has over three decades of experience in regulatory and clinical strategy.
- He brings extensive expertise from his roles at AstraZeneca, PhRMA, and others.
- Seaport’s pipeline focuses on novel treatments for depression and anxiety.
Source: Business Wire
Notable Quotes
- “It is our pleasure to welcome David Wheadon to our Board of Directors. David brings extensive regulatory expertise, and a successful background in the development and approval of several important neuropsychiatric medicines which will benefit Seaport as we advance our clinical-stage pipeline.” — Daphne Zohar, Founder and Chief Executive Officer at Seaport
- “He has an accomplished career and an astute understanding of the regulatory and clinical landscape, which will make him a valuable addition to Seaport as we continue to advance our novel neuropsychiatric medicines through clinical development.” — Steve Paul, M.D., Founder and Chair of the Board at Seaport
SoHC's Take
The appointment of Dr. David Wheadon to Seaport Therapeutics’ Board of Directors is a strategic move that strengthens the company’s leadership as it advances its innovative neuropsychiatric treatments. Dr. Wheadon’s extensive background in regulatory affairs and clinical development will be crucial in navigating the complex processes of bringing Seaport’s promising pipeline of antidepressants and anxiolytics to market. His experience at AstraZeneca and other major pharmaceutical organizations adds significant credibility to Seaport’s mission of addressing unmet needs in mental health treatment.
